Hosted on MSN
Should You Buy Exact Sciences Stock Before Nov. 3?
Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...
Zacks Investment Research on MSN
Gilead Sciences (GILD) stock declines while market improves: Some information for investors
Gilead Sciences (GILD) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, ...
On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...
Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening ...
KIEV, UKRAINE - 2019/01/16: In this photo illustration, the Edwards Lifesciences Medical device company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA ...
Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...
Sight Sciences stock surged on Medicare coverage for TearCare—opening a big dry eye market. Learn more about the company.
Madison, Wis.-based Exact Sciences saw shares increase 12 percent after Minnetonka, Minn.-based UnitedHealthcare said it would cover the company’s colon cancer screening test Cologuard, according to a ...
Exact Sciences Corp (NASDAQ:EXAS) reported fourth-quarter financial results after the market close on Wednesday. Here’s a look at the key details from the quarter. Q4 Earnings: Exact Sciences reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results